[go: up one dir, main page]

FI970918L - Föreningar och förfarande för behandling av cancer - Google Patents

Föreningar och förfarande för behandling av cancer Download PDF

Info

Publication number
FI970918L
FI970918L FI970918A FI970918A FI970918L FI 970918 L FI970918 L FI 970918L FI 970918 A FI970918 A FI 970918A FI 970918 A FI970918 A FI 970918A FI 970918 L FI970918 L FI 970918L
Authority
FI
Finland
Prior art keywords
compounds
methods
treating cancer
cancer
treating
Prior art date
Application number
FI970918A
Other languages
English (en)
Finnish (fi)
Other versions
FI970918A0 (sv
Inventor
Chung K Chu
Yung-Chi Cheng
Original Assignee
Univ Georgia
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,298 external-priority patent/US5817667A/en
Application filed by Univ Georgia, Univ Yale filed Critical Univ Georgia
Publication of FI970918A0 publication Critical patent/FI970918A0/sv
Publication of FI970918L publication Critical patent/FI970918L/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
FI970918A 1994-09-06 1997-03-04 Föreningar och förfarande för behandling av cancer FI970918L (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/301,298 US5817667A (en) 1991-04-17 1994-09-06 Compounds and methods for the treatment of cancer
US39063395A 1995-02-17 1995-02-17
PCT/US1995/011464 WO1996007413A1 (en) 1994-09-06 1995-09-05 Compounds and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
FI970918A0 FI970918A0 (sv) 1997-03-04
FI970918L true FI970918L (sv) 1997-05-02

Family

ID=26972285

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970918A FI970918L (sv) 1994-09-06 1997-03-04 Föreningar och förfarande för behandling av cancer

Country Status (31)

Country Link
US (3) US6063787A (sv)
EP (2) EP1468687A1 (sv)
JP (1) JP3979662B2 (sv)
KR (1) KR100374477B1 (sv)
CN (3) CN1827108A (sv)
AP (1) AP783A (sv)
AT (1) ATE267015T1 (sv)
AU (1) AU704977B2 (sv)
BG (1) BG63122B1 (sv)
BR (1) BR9508886A (sv)
CA (1) CA2199117C (sv)
CZ (1) CZ297873B6 (sv)
DE (1) DE69533066T2 (sv)
DK (1) DK0781136T3 (sv)
ES (1) ES2219666T3 (sv)
FI (1) FI970918L (sv)
HU (1) HUT77172A (sv)
IL (1) IL115156A (sv)
IS (1) IS2011B (sv)
MY (1) MY121548A (sv)
NO (1) NO313268B1 (sv)
NZ (1) NZ335013A (sv)
OA (1) OA10473A (sv)
PL (2) PL188359B1 (sv)
PT (1) PT781136E (sv)
RO (1) RO118748B1 (sv)
RU (1) RU2168995C2 (sv)
SI (1) SI0781136T1 (sv)
SK (1) SK284564B6 (sv)
WO (1) WO1996007413A1 (sv)
ZA (1) ZA957483B (sv)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
AU9016998A (en) 1997-08-08 1999-03-01 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
DE69900841T2 (de) 1998-01-23 2002-10-02 Newbiotics Inc., San Diego Durch enzymkatalyse erhaltene therapeutische substanzen.
JP2002504558A (ja) 1998-02-25 2002-02-12 エモリー ユニバーシテイ ２’−フルオロヌクレオシド
AU2004201676B2 (en) * 1999-03-29 2006-03-09 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
HUP0201708A3 (en) * 1999-03-29 2005-02-28 Shire Biochem Inc Laval The use of nucleoside analogues for treating leukemia
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
ATE269081T1 (de) 1999-09-24 2004-07-15 Shire Biochem Inc Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
WO2001032153A2 (en) 1999-11-04 2001-05-10 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1634888A3 (en) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
PL361310A1 (en) * 2000-10-13 2004-10-04 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
US7138388B2 (en) 2001-01-19 2006-11-21 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
US6800639B2 (en) * 2001-03-23 2004-10-05 Shire Biochem Inc. Pharmaceutical combination for the treatment of cancer
CN1744902B (zh) * 2001-03-23 2010-05-26 希拉加拿大股份有限公司 治疗癌症的药物组合
AU2002242561A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
US6645972B2 (en) 2001-11-02 2003-11-11 Shire Biochem Inc. Methods of treating leukemia
EP2055300B1 (de) * 2001-11-19 2016-01-27 Medigene AG Arzneimittel enthaltend Isopropylmyristat und ein Catechin
KR100631243B1 (ko) 2002-06-21 2006-10-02 엘지전자 주식회사 비디오 데이터의 재생을 관리하기 위한 데이터 구조를갖는 기록 매체
CN1556988B (zh) 2002-06-21 2011-09-14 Lg电子株式会社 具有用于管理记录在其上面的视频数据的再现的数据结构的记录介质
KR20040000290A (ko) 2002-06-24 2004-01-03 엘지전자 주식회사 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법
US7949231B2 (en) 2002-06-24 2011-05-24 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
JP4312151B2 (ja) 2002-06-28 2009-08-12 エルジー エレクトロニクス インコーポレーテッド 多重経路データの記録及び再生を管理するためのデータ構造を有する記録媒体と、それによって記録し、再生する方法及び装置
JP4431043B2 (ja) 2002-10-14 2010-03-10 エルジー エレクトロニクス インコーポレイティド 記録された複数のオーディオストリームの再生を管理するためのデータ構造を有する光ディスク、それによる記録及び再生方法及び装置
WO2004036578A1 (en) 2002-10-15 2004-04-29 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple graphics streams recorded thereon and recording and reproducing methods and apparatuses
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
JP4242839B2 (ja) 2002-11-12 2009-03-25 エルジー エレクトロニクス インコーポレーテッド 記録された多重再生経路ビデオデータの再生を管理するためのデータ構造を有する記録媒体とそれによる記録及び再生方法及び装置
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
US7606463B2 (en) 2003-02-24 2009-10-20 Lg Electronics, Inc. Recording medium having data structure for managing playback control and recording and reproducing methods and apparatuses
US7693394B2 (en) 2003-02-26 2010-04-06 Lg Electronics Inc. Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses
US7809775B2 (en) 2003-02-27 2010-10-05 Lg Electronics, Inc. Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses
CN100397882C (zh) 2003-02-28 2008-06-25 Lg电子株式会社 具有用于管理记录其上的视频数据的随机/洗牌重现的数据结构的记录媒体以及记录和重现的方法和装置
US7620301B2 (en) 2003-04-04 2009-11-17 Lg Electronics Inc. System and method for resuming playback
ES2391561T3 (es) 2003-10-09 2012-11-27 Medigene Ag Uso de un polifenol para el tratamiento de una lesión cancerosa o pre-cancerosa de la piel
WO2006133092A1 (en) 2005-06-07 2006-12-14 Yale University Methods of treating cancer and other conditions or disease states using lfmau and ldt
WO2007067364A2 (en) * 2005-12-02 2007-06-14 Yale University Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
CN101534835B (zh) * 2006-09-01 2012-05-30 佐治亚大学研究基金会 用于癌症的L-OddC的前药
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
AU2017387549B2 (en) * 2016-12-28 2023-07-06 Transgene Sa Oncolytic viruses and therapeutic molecules
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
GR861255B (en) * 1985-05-15 1986-09-16 Wellcome Found Therapeutic nucleosides
AU570853B2 (en) * 1985-08-26 1988-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
DE3650741T2 (de) * 1985-09-17 2000-10-12 The Wellcome Foundation Ltd., Greenford Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
IN164556B (sv) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
FR2601385B1 (fr) * 1986-07-09 1989-09-29 Sucre Rech & Dev Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
EP0342203B1 (en) * 1987-03-24 1994-07-06 Nycomed Imaging As 2',3' dideoxyribofuranoxide derivatives
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
EP0375329B1 (en) * 1988-12-19 1995-05-31 The Wellcome Foundation Limited Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
AU1596495A (en) * 1993-12-30 1995-07-17 Genta Incorporated Improved process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use

Also Published As

Publication number Publication date
CN1111409C (zh) 2003-06-18
PL189288B1 (pl) 2005-07-29
NO971015L (no) 1997-03-05
DE69533066T2 (de) 2005-06-02
IL115156A (en) 2000-07-16
SK284564B6 (sk) 2005-06-02
BR9508886A (pt) 1997-12-30
OA10473A (en) 2002-04-08
US8076347B2 (en) 2011-12-13
KR100374477B1 (ko) 2003-06-19
JPH10506385A (ja) 1998-06-23
KR970705393A (ko) 1997-10-09
CN1827108A (zh) 2006-09-06
CZ63397A3 (en) 1997-07-16
ATE267015T1 (de) 2004-06-15
CZ297873B6 (cs) 2007-04-18
NO971015D0 (no) 1997-03-05
HUT77172A (hu) 1998-03-02
IS2011B (is) 2005-05-13
CN1160351A (zh) 1997-09-24
ZA957483B (en) 1997-06-06
BG63122B1 (en) 2001-04-30
EP1468687A1 (en) 2004-10-20
PL318971A1 (en) 1997-07-21
US6063787A (en) 2000-05-16
AP9700939A0 (en) 1997-04-30
EP0781136A1 (en) 1997-07-02
SI0781136T1 (en) 2004-08-31
EP0781136A4 (en) 1999-06-23
AP783A (en) 1999-11-17
FI970918A0 (sv) 1997-03-04
SK28197A3 (en) 1997-09-10
US20050261320A1 (en) 2005-11-24
BG101284A (en) 1998-03-31
CA2199117C (en) 2006-04-11
US7262213B2 (en) 2007-08-28
DK0781136T3 (da) 2004-08-02
DE69533066D1 (de) 2004-06-24
WO1996007413A1 (en) 1996-03-14
CN1251680C (zh) 2006-04-19
NO313268B1 (no) 2002-09-09
CN1448142A (zh) 2003-10-15
NZ335013A (en) 2000-07-28
MY121548A (en) 2006-02-28
PT781136E (pt) 2004-09-30
US20080171758A1 (en) 2008-07-17
EP0781136B1 (en) 2004-05-19
IS4434A (is) 1997-03-04
IL115156A0 (en) 1995-12-31
AU704977B2 (en) 1999-05-13
RO118748B1 (ro) 2003-10-30
PL188359B1 (pl) 2005-01-31
ES2219666T3 (es) 2004-12-01
CA2199117A1 (en) 1996-03-14
AU3586295A (en) 1996-03-27
JP3979662B2 (ja) 2007-09-19
RU2168995C2 (ru) 2001-06-20

Similar Documents

Publication Publication Date Title
FI970918L (sv) Föreningar och förfarande för behandling av cancer
FI971568L (sv) Förfarande för behandling av resistenta tumörer
NO984431D0 (no) FremgangsmÕte for behandling av smerte
FI970762L (sv) Spido-azabicykliska föreningar som är användbara i terapi
FI952996L (sv) Förfarande för avfallsbehandling
DE69529857D1 (de) Strahlentherapie-System
NO973836L (no) Benzopyran-inneholdende forbindelser og fremgangsmåte for anvendelse derav
FI972484L (sv) Skötsel av karcinom
FI970534L (sv) Förfaranden och kompositioner som är användbara vid profylax och behandling av endotoxinrelaterade tillstånd
FI965008L (sv) Sammansättningar och förfaranden för tumörbehandling
FI951060L (sv) Formulationer och behandlingsmetoder
FI960658L (sv) Nya bis-naftalimider för behandling av cancer
ID17723A (id) Senyawa untuk pengobatan
NO984446D0 (no) FremgangsmÕte for behandling av smerte
IS4789A (is) Meðferðarefnasambönd
NO982582D0 (no) FremgangsmÕte for behandling av smerte
AU5369498A (en) Compounds and methods for treating cancer
ID16924A (id) Metode perlakuan poliolefin
FI970098L (sv) Metod och förening för behandling av håravfall
BR9510494A (pt) Conjunto de elementos de irradiação
FI964783L (sv) Förfarande för behandling av cancer genom reglering av p53-protein
EE200000074A (et) Meetod ja seade jäätmete töötlemiseks
FI963550L (sv) Avfallsbehandlingsmedel
KR970702940A (ko) 스트립 처리장치(strip treating apparatus)
BR9505158A (pt) Complexo inorgânico para tratamento de tumores